44227 Dortmund, de
+49 (231) 9742-6300
Protagen AG Appoints Bernhard Kirschbaum as New Chairman and Oliver Schacht as New Board Member
Dr. Schacht successfully completed the IPO of Curetis in November last year, and served previously in executive positions at Epigenomics Inc., Seattle WA, USA and Epigenomics AG, Berlin. He is a member of the Executive Board of BioDeutschland and has a proven track record in the diagnostics industry, with a strong network in the international capital markets, business development, and sales. "Protagen has recently launched its first proprietary CE-IVD marked products and the Protagen platform is able to continuously deliver novel, clinically validated biomarkers in a market that is in need for novel content," said Dr. Schacht. "I look forward to supporting the management team and board in translating their efforts into a sustainable commercial success."
Stefan Müllner, CEO of Protagen, added: "Having successfully executed two IPOs in the diagnostic field, Oliver Schacht will provide invaluable guidance for an effective and targeted expansion of our business."
Bernhard Kirschbaum, new Chairman of the Protagen Board, commented: "I would like to welcome Oliver Schacht in his new role. Oliver is a great addition to the Board and will help us to grow the business in the demanding field of autoimmune diagnostics. Having served as Chairman of the Board for the last 15 years, Axel Kleemann was the key person who shaped Protagen. We would like to sincerely thank him for his long standing commitment and guidance and I am truly sad to see him leave."
The use of information published here for personal information and editorial processing is generally free of charge. Please clarify any copyright issues with the stated publisher before further use. In the event of publication, please send a specimen copy to email@example.com.